Pfizer Inc engages in biopharmaceutical research. The company delivers value to the customer through the advancement of health care products such as vaccines, medicines, and therapy chemicals employed to treat various conditions. The company also produces ingredients for other companies to develop medicinal drugs, chemotherapy, birth control treatments, and manufacturing services in the health care industry. The company also offers manufacturing and production services for companies with designs for drugs but that lack the capacity to execute the development of the final product. The company is a profitable enterprise. Recently the company has benefited greatly from voluminous sales of the Pfizer Covid Vaccine. In 2020, the company reported $41908 for the year ended December 2020 (Market Line, 2021). The revenues signify an increase of 1.8% compared to the financial year 2019 (Market Line, 2021). Pfizer improves the quality of life for its customers and their dependents both directly and indirectly through research and development of healthcare products used to protect against various conditions, heal existing conditions, manage pain, and save lives at best.

The most important strength for Pfizer is its massive research and development capacities. The company has a reputation for innovative health products that drive its business performance over time. Pfizer’s research and development focuses on developing new models for medical collaboratiuon and the delivery of a rnaeg of therapies and vaccines that advance its ability to deliver value to the customer. The company has cooperative interactions with universities and other institutions of interest to the pharmaceutical industry through third-party contracts. These cooperation and contracts allow it to take advantage of additional research and development capabilities. The company further commands a huge operating performance and capital. These can help the research and development team bring new innovative products to the market, allowing the company to gain and maintain a competitive advantage.

Figure 1: Image of SWOT analysis from Market Line

Pfizer has the capacity necessary to develop a cure for COVID-19. Over the world, people are dying every day due to the direct or indirect impacts of COVID-19. This is the third year that people’s pandemic has been ravaging the world and taking lives daily. The death toll has surpassed the hundreds of thousands. So far, researchers and experts have only managed to develop vaccines whose efficiency ranges from 60% to 96%. Vaccinated persons have been found to get infected, with the only advantage being the lesser severity of the effects of the virus (CDC, 2020). Pfizer has an opportunity to deploy its research and development resources to develop a cure for the pandemic. Over the world, people have recovered from COVID through prolonged doses in the hospital featuring multiple treatments with antibiotics. Pfizer can offer patients something better in the form of a one-shot 1-time treatment for COVID.

The market does not have any other such treatment, and the world is recording over 10000 infections daily. Pfizer would make a huge profit if they could tap supply just half of that population with the cure even at the cost of $10 per dose. Five thousand doses per day would mean 50000 dollars of revenue per day. Although the sales would diminish as the infection rates reduce, the company can make billions by the time the pandemic dies down. Assuming a $5 profit per dose would translate into $25000 in profit per day. While it is not easy to approximate how many people would afford the cure, the product would increase profits at least for the next couple of years as the world struggles to contain the spread of COVID_19.

References:
CDC. (2020, February 11). COVID-19 vaccination.. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure-effectiveness/breakthrough-cases.html

MarketLine Company Profile: Pfizer Inc. (2021). In Pfizer Inc. MarketLine Company Profile (pp. 1–89).

Pfizer Inc. SWOT Analysis. (2021). Pfizer Inc. SWOT Analysis, 1–8.